Skip to main content

Table 2 Baseline clinical characteristics

From: The effects of commercially available footwear on foot pain and disability in people with gout: a pilot study

  Value
Age, years, mean (SD) 57 (13)
Male, n (%) 33 (92%)
Ethnicity, n (%) 15 (42%) European
7 (19%) Māori
9 (25%) Pacific
5 (14%) Asian
BMI, (kg/m2), mean (SD) 34 (8)
Cardiovascular disease, n (%) 16 (44%)
Type 2 diabetes, n (%) 7 (19%)
Diuretic use, n (%) 9 (25%)
Urate-lowering therapy use, n (%) 34 (94%)
Colchicine use, n (%) 23 (64%)
Prednisone use, n (%) 10 (28%)
NSAID use, n (%) 22 (61%)
Serum urate, mmol/l, mean (SD) 0.39 (0.13)
Disease duration, years, mean (SD) 15 (11)
Age at first episode, years, mean (SD) 42 (19)
Self-reported flares in preceding 2 months, mean (SD) 3.9 (10.8)
Days off work in last two months, mean (SD) 0.3 (1.5)
In paid employment, n (%) 17 (47%)
Aspirate proven, n (%) 11 (31%)
Foot tophus count, mean (SD) 1.3 (1.8)
Total tophus count, mean (SD) 4.5 (4.1)
Any subcutaneous tophus, n (%) 26 (72%)